Skip to main content
Figure 1 | Journal of Hematology & Oncology

Figure 1

From: CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells

Figure 1

Impact of anti-CD44 on intra-marrow growth of EL4 and EL4-v10. (A) CD44 is composed of a cytoplasmic domain (CP), a transmembrane domain (TM), and an extracellular domain that is composed of a stalk like and a globular region. The HA binding site is located in the globular region. Variant exon products are inserted in the stalk like region. (B) CD44 and CD44v10 expression in EL4 and EL4-v10 cells: flow cytometry, mean ± SD of % stained cells and intensity of staining (triplicates) and example. (C,D) Homing of i.v. injected CFSE-labeled EL4/EL4-v10 (1×107) was evaluated after 48 h and 72 h in dispersed lymphatic organs by flow cytometry, mean ± SD of the % CFSE-labeled tumor cells/organ (3 mice/group); (B) significant differences (p <0.05) between EL4 versus EL4-v10: s; (D) significant inhibition (p <0.05) by concomitant i.v. antibody (100 μg/mouse) application: *. (E,F) Mice received an i.v. injection of 1×106 EL4/EL4-v10 and 2×/week 100 μg IM7 or K926; the first injection following 1 h after tumor cell application; (E) survival time and rate of 5 mice/group; (F) survival time (mean ± SD), significant differences by IM7 or K926 as well as differences between EL4 versus EL4-v10 (ns: not significant) and between IM7 versus K926 in EL4-v10 bearing mice (p 0.038) are indicated. (G) Recovery of tumor cells in femur and spleen 2 wk after tumor cell application was evaluated by flow cytometry; the mean number ± SD of 3 mice/group is shown; significant differences (p <0.05) by IM7 or K926 application: *; differences between IM7 and K926 were not significant (ns). EL4 and EL4-v10 preferentially home into BM and spleen. Anti-panCD44 (IM7) and anti-CD44v10 (K926) prolong the survival time, with K926 showing higher efficacy in EL4-v10 inoculated mice.

Back to article page